# Precision Biosciences Inc. (DTIL)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $79M  
**Price:** $6.15 (-4.65%)

> Precision BioSciences Inc. is a clinical-stage biotechnology company specializing in in vivo gene editing therapies for genetic and infectious diseases with high unmet medical needs. It leverages its proprietary ARCUS genome editing platform, derived from engineered homing endonucleases, to enable precise DNA modifications including gene insertion, elimination, and excision in both dividing and non-dividing cells. This platform supports sophisticated edits such as high-frequency transgene insertion via homology-directed repair, viral genome removal, and large gene segment excision using single AAV vectors. Key wholly owned programs include PBGENE-HBV, targeting chronic hepatitis B by eliminating covalently closed circular DNA and inactivating integrated HBV DNA via lipid nanoparticles, and PBGENE-DMD, a muscle-targeted therapy for Duchenne muscular dystrophy that excises exons 45–55 to restore near full-length dystrophin. Precision BioSciences Inc. also licenses ARCUS to partners like iECURE for programs such as ECUR-506 in neonatal onset ornithine transcarbamylase deficiency, and maintains non-core ex vivo CAR T initiatives like azer-cel for oncology and autoimmune conditions. Founded in 2006 and headquartered in Durham, North Carolina, the company focuses on developing lasting cures where current treatments fall short.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $34M | — | -$52M | -$46M | — |
| 2024 | $69M | — | -$26M | $7M | — |
| 2023 | $49M | — | -$44M | -$61M | — |
| 2022 | $25M | — | -$62M | -$112M | — |
| 2021 | $116M | — | -$39M | -$31M | — |
| 2020 | $24M | — | -$110M | -$109M | — |
| 2019 | $22M | — | -$87M | -$93M | — |
| 2018 | $11M | — | -$48M | -$46M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $154M | $62M | $92M | $111M | — |
| 2024 | $136M | $80M | $56M | $86M | — |
| 2023 | $160M | $141M | $19M | $117M | — |
| 2022 | $238M | $178M | $60M | $190M | $22M |
| 2021 | $211M | $120M | $91M | $144M | $2M |
| 2020 | $150M | $106M | $44M | $90M | — |
| 2019 | $235M | $97M | $138M | $181M | — |
| 2018 | $139M | $99M | $40M | $103M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$66M | — | — |
| 2024 | -$58M | — | — |
| 2023 | -$84M | — | — |
| 2022 | -$46M | — | — |
| 2021 | -$11M | — | — |
| 2020 | -$87M | — | — |
| 2019 | -$71M | — | — |
| 2018 | -$52M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/DTIL)